▲ +93.04% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Alector in the last 3 months. The average price target is $33.67, with a high forecast of $41.00 and a low forecast of $31.00. The average price target represents a 93.04% upside from the last price of $17.44.
The current consensus among 7 contributing investment analysts is to buy stock in Alector.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.